Trial reportCancer discovery2020
Efficacy and Determinants of Response to HER Kinase Inhibition in
Registry-linked trialOpen access · greenAbstract readClinical Trial, Phase IIMulticenter Study
In one paragraph
Trial report in Cancer discovery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01953926 (An Open-Label, Phase 2 Basket Study of Neratinib in Patients With Solid Tumors With Somatic Activating HER Mutations), which is not on this map. Cited by 72 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed, 2 pooled it
5.8field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Open-Label, Phase 2 Basket Study of Neratinib in Patients With Solid Tumors With Somatic Activating HER Mutations
Who cites it
72 citing papers in PubMed, 2 syntheses or guidelines pooled it, 108 citations in OpenAlex.
- Precision Oncology Clinical Trials: A Systematic Review of Phase II Clinical Trials with Biomarker-Driven, Adaptive Design.Cancer research and treatment · 2024Pooled it
- Efficacy of anti-HER2 drugs in the treatment of patients with HER2-mutated cancers: a systematic review and meta-analysis.Clinical and experimental medicine · 2023Pooled it
- Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Poziotinib treatment in patients with HER2-positive advanced breast cancer who have received prior anti-HER2 regimens.Breast cancer research and treatment · 2024Trial
- Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial.Gynecologic oncology · 2024Trial
- Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2023Trial
- Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B.JCO precision oncology · 2022Trial
- Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Trial
- Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial.The oncologist · 2021Trial
- Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer.Cancer discovery · 2026Article
- Phase I trial of neratinib plus palbociclib in advanced cancers with HER family alterations.ESMO open · 2025Article
- Revolutionizing Breast Cancer Therapeutics: Intersecting Frontiers of Precision Medicine, Nanotechnology, and Drug Delivery Innovations.Current treatment options in oncology · 2025Review
- Mutational Landscape Assessed in Tumor Tissue and Circulating Tumor DNA During Treatment of Patients with HER2/ERBB2-Mutated Solid Tumors.BMC cancer · 2025Article
- HER2; p53 Co-mutated Cancers Show Increased Histone Acetylation and are Sensitive to Neratinib plus Trastuzumab Deruxtecan.bioRxiv : the preprint server for biology · 2025Article
- Emerging importance of HER3 in tumorigenesis and cancer therapy.Nature reviews. Clinical oncology · 2025Review
- Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors.Cancer research communications · 2025Article
- Beyond Hormone Receptors: liquid biopsy tools to unveil new clinical meanings and empower therapeutic decision-making in Luminal-like metastatic breast cancer.Breast (Edinburgh, Scotland) · 2025Review
- Plasma-based analysis of ERBB2 mutational status by multiplex digital PCR in a large series of patients with metastatic breast cancer.Molecular oncology · 2024Article
- Clinical Practice Recommendations for the Use of Next-Generation Sequencing in Patients with Solid Cancer: A Joint Report from KSMO and KSP.Cancer research and treatment · 2024Review
- Clinical practice recommendations for the use of next-generation sequencing in patients with solid cancer: a joint report from KSMO and KSP.Journal of pathology and translational medicine · 2024Review
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
47 authors at 20 institutions in 7 countries.
Lillian M SmythMemorial Sloan Kettering Cancer Center, New York, New York.ORCID https://orcid.org/0000-0002-0986-9285
Sarina A Piha-PaulThe University of Texas MD Anderson Cancer Center, Houston, Texas.
Helen H WonMemorial Sloan Kettering Cancer Center, New York, New York.ORCID https://orcid.org/0000-0001-5237-7529
Alison M SchramMemorial Sloan Kettering Cancer Center, New York, New York.ORCID https://orcid.org/0000-0002-6070-2413
Cristina SauraVall d'Hebron University Hospital, Vall d'Hebrón Institute of Oncology (VHIO), Barcelona, Spain.ORCID https://orcid.org/0000-0001-8296-5065
Sherene LoiPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0001-6137-9171
Janice LuUniversity of Southern California Norris Comprehensive Cancer Center, Los Angeles, California.
Geoffrey I ShapiroDana-Farber Cancer Institute, Boston, Massachusetts.
Dejan JuricDana-Farber Cancer Institute, Boston, Massachusetts.
Ingrid A MayerVanderbilt-Ingram Cancer Center, Nashville, Tennessee.
Carlos L ArteagaThe University of Texas Southwestern Medical Center Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas.
Macarena I de la FuenteSylvester Comprehensive Cancer Center, University of Miami, Miami, Florida.
Adam M BrufksyUniversity of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, Pennsylvania.
Iben SpanggaardRigshospitalet University Hospital, Copenhagen, Denmark.
Morten Mau-SørensenRigshospitalet University Hospital, Copenhagen, Denmark.ORCID https://orcid.org/0000-0003-2235-1250
Monica ArnedosInstitut Gustave Roussy, Paris, France.ORCID https://orcid.org/0000-0001-5269-1251
Victor MorenoSTART Madrid Fundación Jimenez Diaz, Madrid, Spain.ORCID https://orcid.org/0000-0001-6099-4236
Valentina BoniSTART Madrid Hospital Universitario HM Sanchinarro, Madrid, Spain.ORCID https://orcid.org/0000-0002-8675-0018
Joohyuk SohnYonsei Cancer Center, University College of Medicine, Seoul, Korea.
Lee S SchwartzbergWest Cancer Center, University of Tennessee, Memphis, Tennessee.
Xavier Gonzàlez-FarréHospital Universitari Quirón Dexeus, Barcelona, Spain.ORCID https://orcid.org/0000-0002-5797-7037
Andrés CervantesCIBERONC, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain.ORCID https://orcid.org/0000-0003-3806-3691
François-Clement BidardInstitut Curie, Paris, France.
Alexander N GorelickMemorial Sloan Kettering Cancer Center, New York, New York.ORCID https://orcid.org/0000-0001-6736-8246
Richard B LanmanGuardant Health, Redwood City, California.ORCID https://orcid.org/0000-0001-8122-4329
Rebecca J NagyGuardant Health, Redwood City, California.
Gary A UlanerMemorial Sloan Kettering Cancer Center, New York, New York.
Sarat ChandarlapatyMemorial Sloan Kettering Cancer Center, New York, New York.ORCID https://orcid.org/0000-0003-4532-8053
Komal JhaveriMemorial Sloan Kettering Cancer Center, New York, New York.
Elena I GavrilaMemorial Sloan Kettering Cancer Center, New York, New York.
Catherine ZimelMemorial Sloan Kettering Cancer Center, New York, New York.
S Duygu SelcukluMemorial Sloan Kettering Cancer Center, New York, New York.
Myra MelcerMemorial Sloan Kettering Cancer Center, New York, New York.
Aliaksandra SamoilaMemorial Sloan Kettering Cancer Center, New York, New York.
Yanyan CaiMemorial Sloan Kettering Cancer Center, New York, New York.
Maurizio ScaltritiMemorial Sloan Kettering Cancer Center, New York, New York.ORCID https://orcid.org/0000-0002-5522-1447
Grace MannPuma Biotechnology, Inc., Los Angeles, California.
Feng XuPuma Biotechnology, Inc., Los Angeles, California.
Lisa D EliPuma Biotechnology, Inc., Los Angeles, California.
Melanie DujkaPuma Biotechnology, Inc., Los Angeles, California.
Alshad S LalaniPuma Biotechnology, Inc., Los Angeles, California.
Richard BrycePuma Biotechnology, Inc., Los Angeles, California.
José BaselgaMemorial Sloan Kettering Cancer Center, New York, New York.
Barry S TaylorMemorial Sloan Kettering Cancer Center, New York, New York.
David B SolitMemorial Sloan Kettering Cancer Center, New York, New York.
Funda Meric-BernstamThe University of Texas MD Anderson Cancer Center, Houston, Texas.
David M HymanMemorial Sloan Kettering Cancer Center, New York, New York. dhyman@loxooncology.com.
Memorial Sloan Kettering Cancer Center · USPuma Biotechnology (United States) · USCopenhagen University Hospital · DKDana-Farber Cancer Institute · USGuardant (United States) · USThe University of Texas MD Anderson Cancer Center · USCancer Research Institute · USHebron University · PSHospital Universitario Dexeus · ESHospital Universitario Fundación Jiménez Díaz · ESHospital Universitario HM Sanchinarro · ESINCLIVA Health Research Institute · ESInstitut Curie · FRInstitut Gustave Roussy · FRPeter MacCallum Cancer Centre · AUSylvester Comprehensive Cancer Center · USThe University of Texas Southwestern Medical Center · USUniversity of Southern California · USUPMC Hillman Cancer Center · USVanderbilt University · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MTumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MUnraveling resistance to PI3K-alpha inhibitors in breast cancerR01CA190642 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SCALTRITI, MAURIZIO · 2015 to 2019
$2.2MDefining mechanisms of resistance to hormonal therapy in breast cancerR01CA234361 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHANDARLAPATY, SARAT, SOLIT, DAVID B. · 2019 to 2023
$2.0MNCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA190642NCI NIH HHS R01 CA234361
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsBreast Neoplasms, MaleCell Line, TumorDNA Mutational AnalysisDrug Resistance, NeoplasmDrug SynergismErb-b2 Receptor Tyrosine KinasesEstrogen Receptor AntagonistsFemaleFulvestrantHumansMaleERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesEstrogen Receptor AntagonistsFulvestrantneratinibProtein Kinase InhibitorsQuinolinesReceptors, Estrogen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT01953926ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.